NASDAQ · Medical - Healthcare Information Services

WGS (WGS) Stock

$64.97 +4.99% NASDAQ: WGS Healthcare

Valuation

MetricValue
Price$64.97
Market Cap$1.93B
P/E Ratio32.07
P/B Ratio3.75
P/S Ratio2.65
EPS (TTM)$-0.73
52-Week High$170.87
52-Week Low$32.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-30.42%
ROA-4.37%
ROCE-3.90%
Gross Margin69.74%
Operating Margin-2.76%
Net Margin-17.58%
Debt/Equity0.66
Current Ratio2.46

Annual Financials (USD)

Metric20212022202320242025
Revenue$212.0M$235.0M$203.0M$305.0M$428.0M
Operating Profit$-446.0M$-668.0M$-181.0M$-23.0M$-12.0M
Net Profit$-245.0M$-549.0M$-176.0M$-52.0M$-21.0M
EPS$-74.93$-53.63$-7.23$-1.94$-0.73
Op Margin-210.3%-284.5%-89.2%-7.6%-2.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$554.0M$545.0M$419.0M$419.0M$570.0M
Total Liabilities$166.0M$292.0M$191.0M$174.0M$262.0M
Cash$401.0M$137.0M$100.0M$85.0M$105.0M
Borrowings$33.0M$77.0M$120.0M$116.0M$152.0M

Latest News

GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations Insider Monkey · Jul 21, 2026 GeneDx Holdings Corp. (WGS) Fell Following a Significant Cut in 2026 Guidance Insider Monkey · Jul 17, 2026 GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026 Business Wire · Jul 16, 2026 What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17% Motley Fool · Jun 23, 2026 GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth Business Wire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-190.0M$-319.0M$-180.0M$-28.0M$33.0M
Investing Cash Flow$-42.0M$-156.0M$-49.0M$-36.0M$-81.0M
Financing Cash Flow$65.0M$3.0M$0$1.0M$0
Net Cash Flow$283.0M$-263.0M$-38.0M$-14.0M$20.0M
Free Cash Flow$-211.0M$-333.0M$-186.0M$-34.0M$14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.30
EV / EBITDA-149.03
FCF Yield-2.44%
Quick Ratio2.95
Interest Coverage-4.00
Return 1Y-24.14%
Return 3Y708.87%
Return 5Y-83.92%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%
HNGE $75.11 +1.08% -13.65 $5.81B 0.00%
IMVT $39.24 +1.91% -11.09 $8.06B 0.00%
KYMR $103.40 -3.37% -23.01 $8.51B 0.00%
NAMS $27.98 -7.41% -19.27 $3.27B 0.00%

About WGS

WGS is led by CEO Katherine A. Stueland, employs 1,000 people, headquartered in US, publicly traded since 2020.

WGS stock trades at $64.97 with a market capitalization of $1.93B. The stock is valued at a price-to-earnings (P/E) ratio of 32.07, price-to-book of 3.75, price-to-sales of 2.65. Over the past 52 weeks the stock has ranged between $32.21 and $170.87, and currently trades 62.0% below its 52-week high.

On profitability, WGS generates a return on equity (ROE) of -30.42%, return on capital employed of -3.90%, an operating margin of -2.76%, a net profit margin of -17.58%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides